Literature DB >> 7621323

Vagal control of fasting somatostatin levels.

S A Chung1, G R Greenberg, N E Diamant.   

Abstract

UNLABELLED: The relationship between fasting intestinal motility, plasma concentration of somatostatin and vagal integrity was examined in four conscious dogs. Small intestinal motility was recorded using subserosally implanted bipolar electrodes. The cervical vagosympathetic trunks, previously isolated in skin loops, were blocked by cooling. In the fasted state, peaks in somatostatin concentration were observed during phase III of the migrating myoelectric complex (MMC). During vagal blockade, small intestinal MMCs persisted but with phase II being absent or decreased in duration in the duodenum and upper jejunum. Somatostatin levels significantly decreased to below the basal levels observed prior to blockade. No cycling of somatostatin levels was evident during the period of vagal blockade. Upon termination of vagal cooling, normal motility returned and somatostatin levels returned to their pre-blockade levels. IN
CONCLUSION: (1) plasma somatostatin levels cycle with phase III of the MMC in the upper small intestine; (2) the cycling of fasting somatostatin concentrations is primarily dependent upon intact vagal pathways; and (3) basal plasma somatostatin levels are in part vagally dependent.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7621323     DOI: 10.1111/j.1365-2982.1995.tb00211.x

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  4 in total

1.  An unusual cause of gastroparesis: demyelinating disease of the medulla.

Authors:  K Atkinson; W Romano; I Prokopiw
Journal:  Dig Dis Sci       Date:  1998-07       Impact factor: 3.199

Review 2.  The migrating motor complex: control mechanisms and its role in health and disease.

Authors:  Eveline Deloose; Pieter Janssen; Inge Depoortere; Jan Tack
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-03-27       Impact factor: 46.802

3.  Actions of the 5-hydroxytryptamine 1 receptor agonist sumatriptan on interdigestive gastrointestinal motility in man.

Authors:  J Tack; B Coulie; A Wilmer; T Peeters; J Janssens
Journal:  Gut       Date:  1998-01       Impact factor: 23.059

4.  The hungry stomach: physiology, disease, and drug development opportunities.

Authors:  Gareth J Sanger; Per M Hellström; Erik Näslund
Journal:  Front Pharmacol       Date:  2011-02-18       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.